DRRX:NASDAQ

DURECT Corp.

DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program. Its drug development expertise is being applied primarily to the fields of pain management, central nervous system disorders, acute organ injury and metabolic diseases such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Late-stage development programs include POSIMIR (SABER-bupivacaine) and REMOXY (ORADUR-oxycodone). DURECT's epigenomic regulator program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.
DRRX:NASDAQ

Expert Comments:

headshot of Ed Arce

Ed Arce, H.C. Wainwright & Co.

(4/18/19)
"Recently, on March 27, 2019, DURECT Corp. announced that it began enrollment for a Phase 1b dose-finding trial in nonalcoholic steatohepatitis. . .the company plans to report all data gathered in patients who have completed the trial in an initial data readout in H2/19, including imaging data. Therefore, positive results from this Phase 1b trial could enable the initiation of a new Phase 2 trial in H1/20 with the optimal dosage(s)."

Two recently launched clinical trials, and related conference calls, were reviewed in an H.C. Wainwright & Co. report.
read more >

Ed Arce, H.C. Wainwright & Co.

(4/1/19)
"DURECT Corp. announced the initiation of an open-label, 28-day Phase 1b trial of oral DUR-928 in patients with nonalcoholic steatohepatitis. The company plans to enroll about 20 patients per dose group (low, middle, high) for a total of about 60 patients; initial data from this study, including safety, pharmacokinetics and signals of biologic activity, are expected in H2/19."

The company will discuss the trial when it hosts a conference call about this specific disease indication in April.
read more >
This U.S. study follows encouraging results from a Phase 1b trial in the same indication in Australia.
read more >
headshot of Brian Marckx

Brian Marckx, Zacks Small-Cap Research

(3/13/19)
"DUR-928 is where we continue to believe most of the upside value lies in DURECT Corp. . .the company has recently adopted somewhat of an updated strategy as it relates to DUR-928, which relates to honing its focus on accelerating timelines for those indications which it believes holds the most near-term potential to move into late-stage development with one of those areas being nonalcoholic steatohepatitis." -Zacks Small-Cap RResearch

This California company expects results from clinical trials in liver disease and psoriasis in 2019.
read more >

Francois Brisebois, Laidlaw & Company

(3/8/19)
"We see potential upside as DURECT Corp. should start receiving quarterly single-digit earnout payments on U.S. sales of Indivior's Perseris (Indivior expects peak sales of $200–300M), which launched in the U.S. in February 2019. . .we see 2019 as a key year for DUR-928, which we continue to believe is the main reason to own the stock, and see the current valuation as an interesting buying opportunity."

headshot of Ed Arce

Ed Arce, H.C. Wainwright & Co.

(3/8/19)
"DURECT Corp. reported that an ongoing Phase 2a open-label, multicenter, dose escalating trial (NCT03432260) has progressed to its Part B with severe alcoholic hepatitis (AH) patients in the 90 mg dose group. This decision was based on positive results in both moderate and severe AH patients who were given the 30 mg doses and the rapid pace of enrollment in Part B."

Francois Brisebois, Laidlaw & Company

(2/28/19)
"DURECT Corp. expects to submit its complete response letter (CRL) response in H1/19 and anticipates a six-month U.S. Food and Drug Administration review period. With additional safety data from its PERSIST trial, which was ultimately completed for safety, we are encouraged by DRRX's decision to proceed with a full response to the CRL."

A drug used to treat schizophrenic patients will launch commercially in February in the U.S.
read more >
The change relates to the onset of dosing for patients with different degrees of disease.
read more >

More Expert Comments

Experts Following This Company

headshot of Ed Arce
Ed Arce, Managing Direction and Senior Research Analyst – H.C. Wainwright & Co.
Francois Brisebois, Healthcare Research Analyst – Laidlaw & Company
Patrick Dolezal – LifeSci Capital
headshot of Brian Marckx
Brian Marckx, CFA – Zacks Small-Cap Research
headshot of Grant Zeng
Grant Zeng, Senior Biotech Analyst – Zacks Investment Research, Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

DURECT Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
DUR-928, in Phase 1, is an Endogenous Small Molecule with Compelling Animal Data
 
Two Late Stage Pain Products Addressing Large Markets
 
Company Holds the WW Rights to DUR-928 and POSIMIR